Press releaseGlobe Newswire
Minerva Neurosciences
NERV · NASDAQ
$2.53+$0.21 (+9.05%)TodayMarket closed ·
Prev close $2.32
Latest news
- Press releaseGlobe Newswire
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
- Press releaseGlobe Newswire
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
- Press releaseGlobe Newswire
Minerva Announces Leadership Transition
- Press releaseGlobe Newswire
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
- Press releaseGlobe Newswire
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
- News
Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate
- Press releaseGlobe Newswire
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsEvette Mitkov
Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings
- Press releaseGlobe Newswire
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.